Cell-based drug screenings indicate that tumors displaying c-MET gene amplification are "addicted" to MET signaling and therefore are very sensitive to MET-targeted agents. However, these screenings were conducted in the absence of the MET ligand, hepatocyte growth factor (HGF), which is abundant in the tumor microenvironment. Sensitivity of six MET-addicted human tumor cells to three MET kinase inhibitors (JNJ-38877605, PHA-665752, crizotinib) and one antagonistic anti-MET antibody (DN30 Fab) was analyzed in the absence or presence of HGF, in a stroma-tumor coculture system, and by combining anti-MET drugs with an HGF neutralizing antibody (ficlatuzumab) in human HGF knock-in mice bearing c-MET-amplified tumors. In all models examined, HGF promoted resistance to MET-targeted agents, affecting both their potency and efficacy. HGF-induced resistance was due to restoration of physiologic GAB1-mediated PI3K activation that compensated for loss of aberrant HER3-dependent PI3K signaling. Ficlatuzumab restored sensitivity to MET-targeted agents in coculture systems and overcame resistance to JNJ-38877605, crizotinib, and DN30 Fab in human HGF knock-in mice. These data suggest that c-MET-amplified tumor cells-which normally exhibit ligand-independent, constitutive MET activation-become dependent on HGF for survival upon pharmacologic MET inhibition. Because HGF is frequently overexpressed in human cancer, this mechanism may represent a major cause of resistance to anti-MET therapies. The ability of ficlatuzumab to overcome HGF-mediated resistance generates proof of principle that vertical inhibition of both a tyrosine kinase receptor and its ligand can be therapeutically beneficial and opens new perspectives for the treatment of MET-dependent tumors.

Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs.

CAZZANTI, MANUELA;BERTOTTI, Andrea;COMOGLIO, Paolo;TRUSOLINO, Livio;MICHIELI, Paolo
2014-01-01

Abstract

Cell-based drug screenings indicate that tumors displaying c-MET gene amplification are "addicted" to MET signaling and therefore are very sensitive to MET-targeted agents. However, these screenings were conducted in the absence of the MET ligand, hepatocyte growth factor (HGF), which is abundant in the tumor microenvironment. Sensitivity of six MET-addicted human tumor cells to three MET kinase inhibitors (JNJ-38877605, PHA-665752, crizotinib) and one antagonistic anti-MET antibody (DN30 Fab) was analyzed in the absence or presence of HGF, in a stroma-tumor coculture system, and by combining anti-MET drugs with an HGF neutralizing antibody (ficlatuzumab) in human HGF knock-in mice bearing c-MET-amplified tumors. In all models examined, HGF promoted resistance to MET-targeted agents, affecting both their potency and efficacy. HGF-induced resistance was due to restoration of physiologic GAB1-mediated PI3K activation that compensated for loss of aberrant HER3-dependent PI3K signaling. Ficlatuzumab restored sensitivity to MET-targeted agents in coculture systems and overcame resistance to JNJ-38877605, crizotinib, and DN30 Fab in human HGF knock-in mice. These data suggest that c-MET-amplified tumor cells-which normally exhibit ligand-independent, constitutive MET activation-become dependent on HGF for survival upon pharmacologic MET inhibition. Because HGF is frequently overexpressed in human cancer, this mechanism may represent a major cause of resistance to anti-MET therapies. The ability of ficlatuzumab to overcome HGF-mediated resistance generates proof of principle that vertical inhibition of both a tyrosine kinase receptor and its ligand can be therapeutically beneficial and opens new perspectives for the treatment of MET-dependent tumors.
2014
74
22
6598
6609
http://cancerres.aacrjournals.org/content/early/2014/09/12/0008-5472.CAN-14-0761.long
http://cancerres.aacrjournals.org/content/74/22/6598.full.pdf+html
Animals; Antibodies, Monoclonal; Hepatocyte Growth Factor; Mice; Mice, SCID; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-met; Receptor, ErbB-3; Signal Transduction; Tumor Microenvironment; Cancer Research; Oncology; Medicine (all)
Pennacchietti S;Cazzanti M;Bertotti A;Rideout WM ;Han M;Gyuris J;Perera T;Comoglio PM;Trusolino L;Michieli P
File in questo prodotto:
File Dimensione Formato  
2014_Microenvironment-Derived HGF Overcomes Genetically determined sensitivity to anti-MET drugs.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 2.72 MB
Formato Adobe PDF
2.72 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Cancer Research 2014_pennacchietti.pdf

Open Access dal 16/11/2015

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 1.37 MB
Formato Adobe PDF
1.37 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/149419
Citazioni
  • ???jsp.display-item.citation.pmc??? 32
  • Scopus 57
  • ???jsp.display-item.citation.isi??? 58
social impact